1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Hold On TG’s Program Stems From Existing – Not New – Concerns

‘Sub-par’ Disclosure Draws Analyst Finger Wagging

 
• By Alaric DeArment

TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.

Digital illustration of Cancer cell in colour background
TG disclosed a partial clinical hold on its program to develop Ukoniq/ublituximab in NHL and CLL • Source: Shutterstock

The partial clinical hold on TG Therapeutics, Inc.’s program for PI3K-delta inhibitor Ukoniq (umbralisib) combined with CD20-directed ublituximab – together nicknamed U2 – does not appear to be about any new concerns about Ukoniq. However, it does highlight concerns about the PI3K class overall and the method by which the company disclosed the hold drew criticism.

TG’s CEO Michael Weiss revealed in a fireside chat at B. Riley Securities’ 2022 Virtual Oncology Investor Conference on 27...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

AstraZeneca And Daiichi Sankyo’s Datroway Scores Survival Success In TNBC

 
• By Andrew McConaghie

Its overall survival win for Datroway could be an advantage over Gilead’s Trodelvy in triple negative breast cancer.

Jazz Looks To Label Expansion To Reverse Zepzelca Sales Slump

 
• By Alaric DeArment

The FDA approved the drug for combination with Roche’s Tecentriq in first-line maintenance of extensive-stage small cell lung cancer, while the NCCN added the combination to its treatment guidelines.

Attractiveness of Cell Therapy In The Spotlight With Limited Interest In Galapagos Unit

 
• By Kevin Grogan

Non-binding offers have come mostly from groups of financial investors rather than biopharma players.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.